Parameter optimization of vibration control system for adjacent building structures based on negative stiffness inerter damper.

Building structures are subjected to strong earthquakes, which result in lateral collisions between them. Such collisions often cause severe structural damage and exacerbate the seismic hazard risk of building structures during earthquake events. This paper discusses the application of vibration control devices based on negative stiffness inerter damper in single-story adjacent building structures. The dynamic equations of the vibration control system containing different types of negative stiffness inerter damper under seismic excitation are established as a unified model. The H2 norm theory and Monte Carlo pattern search method are used to optimize the design parameters to improve the vibration control performance of the system, and the dynamic characteristics of the system are investigated. The results demonstrate that attaching negative stiffness inerter damper to adjacent building structures can effectively improve the overall seismic capacity reserve of the building and reduce the risk of collision of adjacent building structures; improve the robustness and stability of the system, and better reduce the displacement response of the building structure under seismic excitation. In addition, the potential of NSID-based vibration control devices to convert seismic energy into usable electricity has been investigated.

Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.

Introduction: Although third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected stage IIIA non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, the optimal treatment sequencing of EGFR-TKIs, particularly whether Osimertinib should be the initial or sequential therapy following the first-generation EGFR-TKIs remains uncertain. Methods: A retrospective analysis was conducted on a cohort of patients with EGFR-mutated stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or Osimertinib (third-generation) alone, or in sequential combination, at a single institution. The data analysis involved using the Kaplan-Meier method, log-rank test, and Cox regression. Results: Out of the total 148 patients with stage IIIA NSCLC included in the study, 76 individuals underwent treatment with either first-generation EGFR-TKIs (referred to as subgroup "1″) or exclusively Osimertinib (subgroup "0 + 3″), or a sequential combination of the two (subgroup "1 + 3″) following surgery. Both univariate and multivariate analyses demonstrated that there were no discernible disparities in terms of disease-free survival and overall survival between subgroup " 1″ and " 1 + 3," nor between subgroup " 0 + 3″ and "1 + 3". Conclusion: The findings from this study indicate that the introduction of third-generation EGFR-TKI Osimertinib did not yield enhanced survival benefits when compared to the first-generation drug in patients with stage IIIA completely resected NSCLC who were administered EGFR-TKIs as part of their postoperative adjuvant treatment. Additionally, within the observed sample size of this cohort, the sequential use of Osimertinib alongside first-generation EGFR-TKI did not demonstrate superiority over using either the first-generation EGFR-TKI or Osimertinib alone in terms of postoperative survival.